A cost-consequence analysis of different screening procedures in Alzheimer’s Disease: Results from the MOPEAD project

Manuscript Number: 

21-0303R2

Author(s): 
Mark Belger, Mercè Boada, Jaka Bon, Annette Dumas, Miren Gurruchaga Telleria, Laura Jamilis, Frank Jessen, Gunilla Johansson, Milica G. Kramberger, Adrián Rodrigo Salas, Octavio Rodríguez-Gómez, Lena Sannemann, Malou Stoekenbroek, Sergi Valero, Lisa Vermunt, Pieter Jelle Visser, Lisa Waterink, Anders Wimo, Bengt Winblad, Marissa Zwan

Disclosures

Mark Belger

  • Equity:
    I am a shareholder at Eli Lilly
    Sponsors:
    I am an employee and minor shareholder of Eli Lilly

Mercè Boada

  • Consulting Fees:
    GRIFOLS, ROCHE, BIOGEN, CORTEXYME, MERCK, LILLY, ZAMBON
    Lecture Fees:
    GRIFOLS, ROCHE, BIOGEN,
    Grants
    • Agency: 
      GRIFOLS,
      Dates: 
      Received by the entity
    • Agency: 
      LaCaixa
      Dates: 
      Received by the entity
    • Agency: 
      IMI
      Dates: 
      Received by the entity
    • Agency: 
      ISCIII
      Dates: 
      Received by the entity

Jaka Bon

  • Nothing to Disclose

Annette Dumas

  • Nothing to Disclose

Miren Gurruchaga Telleria

  • Nothing to Disclose

Laura Jamilis

  • Nothing to Disclose

Frank Jessen

  • Nothing to Disclose

Gunilla Johansson

  • Nothing to Disclose

Milica G. Kramberger

  • Nothing to Disclose

Adrián Rodrigo Salas

  • Nothing to Disclose

Octavio Rodríguez-Gómez

  • Nothing to Disclose

Lena Sannemann

  • Grants
    • Agency: 
      IMI2 Grant Agreement Number 115985 for MOPEAD
      Dates: 
      01/10/2016 - 31/12/2019

Malou Stoekenbroek

  • Nothing to Disclose

Sergi Valero

  • Nothing to Disclose

Lisa Vermunt

  • Grants
    • Agency: 
      Olink
      Dates: 
      2021

Pieter Jelle Visser

  • Nothing to Disclose

Lisa Waterink

  • Nothing to Disclose

Anders Wimo

  • Consulting Fees:
    Biogen 2018 Eisai 2019
    Patents/Royalties
    RUD instrument
    Grants
    • Agency: 
      MSD
      Dates: 
      2017-2019

Bengt Winblad

  • Consulting Fees:
    I( am part of SAB for Alzhemed, Axon Neuroscience, Biogen and Resverlogix.

Marissa Zwan

  • Nothing to Disclose